Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.43M | 2.39M | 3.74M | 3.23M | 2.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.12M | 3.37M | 4.76M | 4.24M | 3.48M |
| Operating Income | -3.12M | -3.37M | -4.76M | -4.24M | -3.48M |
| Income Before Tax | 5.46M | 1.37M | -5.55M | -8.61M | -8.33M |
| Income Tax Expenses | -- | -- | -- | -- | -2.50K |
| Earnings from Continuing Operations | 5.46 | 1.37 | -5.55 | -8.61 | -8.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.46M | 1.37M | -5.55M | -8.61M | -8.33M |
| EBIT | -3.12M | -3.37M | -4.76M | -4.24M | -3.48M |
| EBITDA | -3.08M | -3.32M | -3.21M | -2.30M | -1.20M |
| EPS Basic | 2.83 | 2.00 | -1.04 | -2.34 | -1.98 |
| Normalized Basic EPS | -0.28 | -0.61 | -0.46 | -1.27 | -1.04 |
| EPS Diluted | 2.83 | 2.00 | -1.04 | -2.34 | -1.98 |
| Normalized Diluted EPS | -0.28 | -0.61 | -0.46 | -1.27 | -1.04 |
| Average Basic Shares Outstanding | 7.48M | 9.37M | 12.79M | 16.25M | 19.80M |
| Average Diluted Shares Outstanding | 7.48M | 9.37M | 12.79M | 16.25M | 19.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |